Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
| In millions, except per share items | Sep-30-22 | Sep-30-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 | Sep-30-16 | Sep-30-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Medical | 8,841.0 | 8,361.0 | 7,637.0 | 9,064.0 | 8,616.0 | 7,419.0 | 7,965.0 | 6,460.0 |
| Life Sciences | 5,564.0 | 6,530.0 | 4,675.0 | 4,300.0 | 4,330.0 | 3,988.0 | 3,829.0 | 3,822.0 |
| Interventional | 4,464.0 | 4,239.0 | 3,762.0 | 3,926.0 | 3,037.0 | 685.0 | 689.0 | |
| Total revenues | 18,870.0 | 19,131.0 | 16,074.0 | 17,290.0 | 15,983.0 | 12,093.0 | 12,483.0 | 10,282.0 |
| Revenue growth [+] | -1.4% | 19.0% | -7.0% | 8.2% | 32.2% | -3.1% | 21.4% | 21.7% |
| Medical | 5.7% | 9.5% | -15.7% | 5.2% | 16.1% | -6.9% | 23.3% | 41.3% |
| Life Sciences | -14.8% | 39.7% | 8.7% | -0.7% | 8.6% | 4.2% | 0.2% | -1.3% |
| Interventional | 5.3% | 12.7% | -4.2% | 29.3% | 343.4% | -0.6% | | |
| Cost of goods sold | 10,393.0 | 10,500.0 | 9,276.0 | 9,002.0 | 8,714.0 | 6,128.0 | 6,492.0 | 5,587.0 |
| Gross profit | 8,477.0 | 8,631.0 | 6,798.0 | 8,288.0 | 7,269.0 | 5,965.0 | 5,991.0 | 4,695.0 |
| Gross margin | 44.9% | 45.1% | 42.3% | 47.9% | 45.5% | 49.3% | 48.0% | 45.7% |
| Selling, general and administrative | 4,709.0 | 4,719.0 | 4,185.0 | 4,332.0 | 4,016.0 | 2,909.0 | 3,005.0 | 2,563.0 |
| Research and development | 1,256.0 | 1,279.0 | 1,039.0 | 1,062.0 | 1,004.0 | 770.0 | 828.0 | 632.0 |
| Other operating expenses | 230.0 | 383.0 | 662.0 | 1,134.0 | 740.0 | 764.0 | 728.0 | 426.0 |
| EBITDA [+] | 4,511.0 | 4,480.0 | 3,027.0 | 4,013.0 | 3,487.0 | 2,610.0 | 2,544.0 | 1,965.0 |
| EBITDA growth | 0.7% | 48.0% | -24.6% | 15.1% | 33.6% | 2.6% | 29.5% | -9.4% |
| EBITDA margin | 23.9% | 23.4% | 18.8% | 23.2% | 21.8% | 21.6% | 20.4% | 19.1% |
| Depreciation | 799.0 | 828.0 | 731.0 | 756.0 | 723.0 | 535.0 | 562.0 | 545.0 |
| EBITA | 3,712.0 | 3,652.0 | 2,296.0 | 3,257.0 | 2,764.0 | 2,075.0 | 1,982.0 | 1,420.0 |
| EBITA margin | 19.7% | 19.1% | 14.3% | 18.8% | 17.3% | 17.2% | 15.9% | 13.8% |
| Amortization of intangibles | 1,430.0 | 1,402.0 | 1,384.0 | 1,497.0 | 1,255.0 | 553.0 | 552.0 | 346.0 |
| EBIT [+] | 2,282.0 | 2,250.0 | 912.0 | 1,760.0 | 1,509.0 | 1,522.0 | 1,430.0 | 1,074.0 |
| EBIT growth | 1.4% | 146.7% | -48.2% | 16.6% | -0.9% | 6.4% | 33.1% | -33.1% |
| EBIT margin | 12.1% | 11.8% | 5.7% | 10.2% | 9.4% | 12.6% | 11.5% | 10.4% |
| Interest expense, net [+] | 382.0 | 460.0 | 521.0 | 627.0 | 641.0 | 445.0 | 367.0 | 356.0 |
| Interest expense | 398.0 | 469.0 | 528.0 | 639.0 | 706.0 | 521.0 | 388.0 | 371.0 |
| Interest income | 16.0 | 9.0 | 7.0 | 12.0 | 65.0 | 76.0 | 21.0 | 15.0 |
| Other income (expense), net | -117.0 | -98.0 | 23.0 | 43.0 | 305.0 | -101.0 | 11.0 | 21.0 |
| Pre-tax income | 1,783.0 | 1,692.0 | 414.0 | 1,176.0 | 1,173.0 | 976.0 | 1,074.0 | 739.0 |
| Income taxes | 148.0 | 88.0 | 62.0 | -57.0 | 862.0 | -124.0 | 97.0 | 44.0 |
| Tax rate | 8.3% | 5.2% | 15.0% | | 73.5% | | 9.0% | 6.0% |
| Net income | 1,689.0 | 2,002.0 | 767.0 | 1,082.0 | 159.0 | 1,030.0 | 976.0 | 695.0 |
| Net margin | 9.0% | 10.5% | 4.8% | 6.3% | 1.0% | 8.5% | 7.8% | 6.8% |
| |
| Basic EPS [+] | $5.93 | $6.92 | $2.75 | $4.01 | $0.62 | $4.70 | $4.59 | $3.43 |
| Growth | -14.4% | 151.7% | -31.4% | 551.3% | -86.9% | 2.5% | 33.7% | -44.0% |
| Diluted EPS [+] | $5.88 | $6.85 | $2.72 | $3.94 | $0.60 | $4.61 | $4.49 | $3.35 |
| Growth | -14.2% | 152.4% | -31.0% | 555.4% | -87.0% | 2.7% | 34.0% | -44.1% |
| |
| Dividends per share [+] | $3.48 | $3.32 | $3.16 | $3.08 | $3.00 | $2.92 | $2.64 | $2.40 |
| Growth | 4.8% | 5.1% | 2.6% | 2.7% | 2.7% | 10.6% | 10.0% | 10.1% |
| |
| Shares outstanding (basic) [+] | 285.0 | 289.3 | 279.0 | 269.9 | 258.4 | 218.9 | 212.7 | 202.5 |
| Growth | -1.5% | 3.7% | 3.3% | 4.5% | 18.0% | 2.9% | 5.0% | 4.8% |
| Shares outstanding (diluted) [+] | 287.4 | 292.1 | 282.4 | 274.8 | 264.6 | 223.6 | 217.5 | 207.5 |
| Growth | -1.6% | 3.4% | 2.8% | 3.8% | 18.4% | 2.8% | 4.8% | 5.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|